Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $144
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni maintains a 'Buy' rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $132 to $144.
September 13, 2023 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a 'Buy' rating on Neurocrine Biosciences and raises the price target from $132 to $144.
The news of Canaccord Genuity maintaining a 'Buy' rating and raising the price target for Neurocrine Biosciences is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100